Company intelligence / Profile preview

Chong Kun Dang Holdings

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

CKD Holdings oversees a portfolio with multiple Phase 1/2 assets including HDAC6 inhibitor CKD-510 (licensed to Novartis), CETP inhibitor CKD-508, and ADC CKD-703; focuses on oncology, metabolic, and immunology through subsidiaries.

Therapeutic areas: ImmunologyCardiovascularEndocrinologyNeurologyOncology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateGene therapy
Industry: Biotech

Partnerships

Novartis (CKD-510)Sinapix (ADC technology)Aclipse Therapeutics (lobeglitazone)BayerRochePfizerMSDAmgenEncell (CGT)

Beyond the preview

Go deeper on Chong Kun Dang Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chong Kun Dang Holdings.

Explore the full profile